Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma

References

• Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report : primary brain and central nervous system tumors diagnosed. Neuro Oncol. 2012;14(suppl 5):v1–v49.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–e523.
   PubMed Web of Science ®Google Scholar
• Fraser G, Varela NP, Dudebout J, et al. Management of primary central nervous system diffuse large B-cell lymphoma (PCNS DLBCL). Toronto (ON): Cancer Care Ontario; 2017. Available from: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/summary/pebcSCT8s.pdf
   Google Scholar
• Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019;184(3):348–363.
   PubMed Web of Science ®Google Scholar
• Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th ed. Ottawa: CADTH; 2017. Available from: https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf
   Google Scholar
• Guyot P, Ades AE, Ouwens M, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
   PubMed Web of Science ®Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials–extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–754.
   PubMed Web of Science ®Google Scholar
• Jackson C. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70(8):1–33.
   Web of Science ®Google Scholar
• Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178–1182.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Life expectancy at various ages, by population group and sex, Canada (Table 13-10-0134-01). Available from: https://doi.org/10.25318/1310013401-eng
   Google Scholar
• Ontario Case Costing Cost Analysis tool. Health Data Branch, Ontario Ministry of Health. Available from: https://hsimi.ca/occp/occpreports/
   Google Scholar
• Earle C, Coyle D, Smith A, et al. The cost of radiotherapy at an Ontario regional cancer centre: a re-evaluation. Crit Rev Oncol Hematol. 1999; 32(2):87–93.
   PubMed Web of Science ®Google Scholar
• Kim JSM, Dong JZ, Brener S, et al. Cost-effectiveness analysis of a reduction in diagnostic imaging in degenerative spinal disorders. Healthc policy. 2011;7(2):e105–21.
   PubMedGoogle Scholar
• Ministry of Health and long-term care. Schedule of benefits: physician services. 2016;2015:71. Available from: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/schedule_master.html
   Google Scholar
• Canadian Institute for Health Information. National Health Expenditure Trends, 1975 to 2017. Data Tables – Series E1. Ottawa (ON): CIHI; 2017. Available from: https://secure.cihi.ca/free_products/nhex2017-trends-report-en.pdf
   Google Scholar
• Prica A, Chan K, Cheung M. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis. Neuro-oncology. 2014;16(10):1384–1391.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. JCO. 2005;23(7):1507–1513.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. JCO. 2003;21(2):266–272.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model. JCO. 2006;24(36):5711–5715.
   PubMed Web of Science ®Google Scholar
• Sanders S, Chua N, Larouche JF, et al. Outcomes of consecutively diagnosed primary central nervous system lymphoma patients using the Alberta lymphoma clinical practice guideline incorporating thiotepa-busulfan conditioning for transplantation-eligible patients. Biol Blood Marrow Transplant. 2019;25:1505–1510.
   PubMed Web of Science ®Google Scholar
• Zeremski V, Koehler M, Fischer T, et al. Characteristics and outcome of patients with primary CNS lymphoma in a “real-life” setting compared to a clinical trial. Ann Hematol. 2016;95(5):793–799.
   PubMed Web of Science ®Google Scholar
• Forsythe A, Brandt PS, Dolph M, et al. Systematic review of health state utility values for acute myeloid leukemia. CEOR. 2018;10:83–92.
   Google Scholar
• Lester-Coll NH, Dosoretz AP, Hayman JA, et al. Health state utilities for patients with brain metastases. Cureus. 2016;8:e667.
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:1–15.
   Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749–759.
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:1–9.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410–420.
   PubMed Web of Science ®Google Scholar
• Bamber L, Muston D, McLeod E. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J. 2015;13(1):1–12.
   PubMedGoogle Scholar
• Tielemans MM, Jaspers Focks J, van Rossum LGM, et al. Gastrointestinal symptoms are still prevalent and negatively impact health-related quality of life: a large cross-sectional population based study in The Netherlands. PLoS One. 2013;8(7):e69876–e69877.
   PubMed Web of Science ®Google Scholar